Skip to main content
Top
Published in: Current Cardiology Reports 11/2021

01-11-2021 | Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

The Global Impact of Rheumatic Heart Disease

Authors: Joselyn Rwebembera, Andrea Z. Beaton, Sarah R. de Loizaga, Rodrigo T. L. Rocha, Nakagaayi Doreen, Isaac Ssinabulya, Emmy Okello, Clara L. Fraga, Bruno F. Galdino, Maria Carmo P. Nunes, Bruno R. Nascimento

Published in: Current Cardiology Reports | Issue 11/2021

Login to get access

Abstract

Purpose of Review

Rheumatic heart disease (RHD) is a neglected disease of poverty, which presents challenges for patients, communities, and health systems. These effects are magnified in low resource countries, which bear the highest disease burden. When considering the impact of RHD, it is imperative that we widen our lens in order to better understand how RHD impacts the over 40 million people currently living with this preventable condition and their communities. We aimed to perform an updated literature review on the global impact of RHD, examining a broad range of aspects from disease burden to impact on healthcare system to socioeconomic implications.

Recent Findings

RHD accounts for 1.6% of all cardiovascular deaths, resulting in 306,000 deaths yearly, with a much higher contribution in low- and middle-income countries, where 82% of the deaths occurred in 2015. RHD can result in severe health adverse outcomes, markedly heart failure, arrhythmias, stroke and embolisms, and ultimately premature death. Thus, preventive, diagnostic and therapeutic interventions are required, although insufficiently available in undersourced settings. As examples, anticoagulation management is poor in endemic regions – and novel oral anticoagulants cannot be recommended – and less than 15% of those in need have access to interventional procedures and valve replacement in Africa.

Summary

RHD global impact remains high and unequally distributed, with a marked impact on lower resourced populations. This preventable disease negatively affects not only patients, but also the societies and health systems within which they live, presenting broad challenges and high costs along the pathway of prevention, diagnosis, and management.
Literature
1.
go back to reference Dick GFDGH. The etiology of scarlet fever. J Am Med Assoc. 1924;82(4):301–2.CrossRef Dick GFDGH. The etiology of scarlet fever. J Am Med Assoc. 1924;82(4):301–2.CrossRef
2.
go back to reference Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5:11.PubMedPubMedCentralCrossRef Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5:11.PubMedPubMedCentralCrossRef
3.
go back to reference Gordis L. Effectiveness of comprehensive-care programs in preventing rheumatic fever. N Engl J Med. 1973;289:331–5.PubMedCrossRef Gordis L. Effectiveness of comprehensive-care programs in preventing rheumatic fever. N Engl J Med. 1973;289:331–5.PubMedCrossRef
4.
go back to reference Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002:CD002227. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002:CD002227.
5.
go back to reference Strasser T, Dondog N, El Kholy A, et al. The community control of rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project. Bull World Health Organ. 1981;59:285–94.PubMedPubMedCentral Strasser T, Dondog N, El Kholy A, et al. The community control of rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project. Bull World Health Organ. 1981;59:285–94.PubMedPubMedCentral
6.
go back to reference • Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021. This study reports the most up-to-date information on the global burden of cardiovascular disease worldwide, depicting current trends for Rheumatic Heart Disease.PubMedPubMedCentralCrossRef • Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021. This study reports the most up-to-date information on the global burden of cardiovascular disease worldwide, depicting current trends for Rheumatic Heart Disease.PubMedPubMedCentralCrossRef
7.
go back to reference Organization WH. Rheumatic fever and rheumatic heart disease. Executive Board, 141st Session: resolutions and decisions, annexes, summary records. Geneva, Switzerland, 2018. Organization WH. Rheumatic fever and rheumatic heart disease. Executive Board, 141st Session: resolutions and decisions, annexes, summary records. Geneva, Switzerland, 2018.
8.
go back to reference Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure. Arch Intern Med. 2012;172:1386–94.PubMedCrossRef Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure. Arch Intern Med. 2012;172:1386–94.PubMedCrossRef
9.
go back to reference Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. 2017;377:713–22.PubMedCrossRef Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. 2017;377:713–22.PubMedCrossRef
11.
go back to reference Baker MG, Gurney J, Oliver J, et al. Risk factors for acute rheumatic fever: literature review and protocol for a case-control study in New Zealand. Int J Environ Res Public Health. 2019;16. Baker MG, Gurney J, Oliver J, et al. Risk factors for acute rheumatic fever: literature review and protocol for a case-control study in New Zealand. Int J Environ Res Public Health. 2019;16.
12.
go back to reference Katzenellenbogen JM, Bond-Smith D, Seth RJ, et al. Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change. J Am Heart Assoc. 2020;9:e016851. Katzenellenbogen JM, Bond-Smith D, Seth RJ, et al. Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change. J Am Heart Assoc. 2020;9:e016851.
13.
go back to reference Wyber R, Noonan K, Halkon C, et al. Ending rheumatic heart disease in Australia: the evidence for a new approach. Med J Aust. 2020;213(Suppl 10):S3–31.PubMed Wyber R, Noonan K, Halkon C, et al. Ending rheumatic heart disease in Australia: the evidence for a new approach. Med J Aust. 2020;213(Suppl 10):S3–31.PubMed
14.
go back to reference Beaudoin A, Edison L, Introcaso CE, et al. Acute rheumatic fever and rheumatic heart disease among children–American Samoa, 2011–2012. MMWR Morb Mortal Wkly Rep. 2015;64:555–8.PubMedPubMedCentral Beaudoin A, Edison L, Introcaso CE, et al. Acute rheumatic fever and rheumatic heart disease among children–American Samoa, 2011–2012. MMWR Morb Mortal Wkly Rep. 2015;64:555–8.PubMedPubMedCentral
15.
go back to reference Reeves BM, Kado J, Brook M. High prevalence of rheumatic heart disease in Fiji detected by echocardiography screening. J Paediatr Child Health. 2011;47:473–8.PubMedCrossRef Reeves BM, Kado J, Brook M. High prevalence of rheumatic heart disease in Fiji detected by echocardiography screening. J Paediatr Child Health. 2011;47:473–8.PubMedCrossRef
16.
go back to reference Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005;112:3584–91.PubMedCrossRef Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005;112:3584–91.PubMedCrossRef
17.
go back to reference Scheel A, Ssinabulya I, Aliku T, et al. Community study to uncover the full spectrum of rheumatic heart disease in Uganda. Heart. 2019;105:60–6.PubMedCrossRef Scheel A, Ssinabulya I, Aliku T, et al. Community study to uncover the full spectrum of rheumatic heart disease in Uganda. Heart. 2019;105:60–6.PubMedCrossRef
18.
go back to reference Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172:1386–94.PubMedCrossRef Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172:1386–94.PubMedCrossRef
19.
go back to reference Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019;9:1–14.CrossRef Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019;9:1–14.CrossRef
20.
go back to reference • Karki P, Uranw S, Bastola S, et al. Effectiveness of systematic echocardiographic screening for rheumatic heart disease in Nepalese schoolchildren: a cluster randomized clinical trial. JAMA Cardiology. 2021;6:420–6. This study is the first large-scale trial testing the strategy of systematic echcardiographic screening on outcomes of individuals with Rheumatic Heart Disease, providing additional evidence to screening in clinical practice, noticeably in endemic settings.PubMedCrossRef • Karki P, Uranw S, Bastola S, et al. Effectiveness of systematic echocardiographic screening for rheumatic heart disease in Nepalese schoolchildren: a cluster randomized clinical trial. JAMA Cardiology. 2021;6:420–6. This study is the first large-scale trial testing the strategy of systematic echcardiographic screening on outcomes of individuals with Rheumatic Heart Disease, providing additional evidence to screening in clinical practice, noticeably in endemic settings.PubMedCrossRef
21.
go back to reference •• Beaton A, Okello E, Engelman D, et al. Determining the impact of benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (goal trial): study protocol for a randomized controlled trial. Am Heart J. 2019;215:95–105. This is the protocol of the first randomized trial evaluating the effects of penicillin on clinical and echocardiographic outcomes of children with subclinical Rheumatic Heart Disease and high-risk features.PubMedCrossRef •• Beaton A, Okello E, Engelman D, et al. Determining the impact of benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (goal trial): study protocol for a randomized controlled trial. Am Heart J. 2019;215:95–105. This is the protocol of the first randomized trial evaluating the effects of penicillin on clinical and echocardiographic outcomes of children with subclinical Rheumatic Heart Disease and high-risk features.PubMedCrossRef
22.
go back to reference Kingue S, Ba SA, Balde D, et al. The VALVAFRIC study: a registry of rheumatic heart disease in Western and Central Africa. Arch Cardiovasc Dis. 2016;109:321–9.PubMedCrossRef Kingue S, Ba SA, Balde D, et al. The VALVAFRIC study: a registry of rheumatic heart disease in Western and Central Africa. Arch Cardiovasc Dis. 2016;109:321–9.PubMedCrossRef
23.
go back to reference Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the global rheumatic heart disease registry (the REMEDY study). Eur Heart J. 2015;36:1115–22.PubMedCrossRef Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the global rheumatic heart disease registry (the REMEDY study). Eur Heart J. 2015;36:1115–22.PubMedCrossRef
24.
go back to reference Okello E, Wanzhu Z, Musoke C, et al. Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda. Cardiovasc J Afr. 2013;24:82. Okello E, Wanzhu Z, Musoke C, et al. Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda. Cardiovasc J Afr. 2013;24:82.
25.
go back to reference Zhang W, Mondo C, Okello E, et al. Presenting features of newly diagnosed rheumatic heart disease patients in Mulago Hospital: a pilot study: cardiovascular topics. Cardiovasc J Afr. 2013;24:28–33.PubMedPubMedCentralCrossRef Zhang W, Mondo C, Okello E, et al. Presenting features of newly diagnosed rheumatic heart disease patients in Mulago Hospital: a pilot study: cardiovascular topics. Cardiovasc J Afr. 2013;24:28–33.PubMedPubMedCentralCrossRef
26.
go back to reference Watkins DA, Beaton AZ, Carapetis JR, et al. Rheumatic heart disease worldwide: JACC scientific expert panel. J Am Coll Cardiol. 2018;72:1397–416.PubMedCrossRef Watkins DA, Beaton AZ, Carapetis JR, et al. Rheumatic heart disease worldwide: JACC scientific expert panel. J Am Coll Cardiol. 2018;72:1397–416.PubMedCrossRef
27.
go back to reference Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–88. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–88.
28.
go back to reference Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S-e600S.PubMedPubMedCentralCrossRef Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S-e600S.PubMedPubMedCentralCrossRef
29.
go back to reference January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32.PubMedCrossRef January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32.PubMedCrossRef
30.
go back to reference Semakula JR, Kisa G, Mouton JP, et al. Anticoagulation in sub-Saharan Africa: are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. Br J Clin Pharmacol. 2021. Semakula JR, Kisa G, Mouton JP, et al. Anticoagulation in sub-Saharan Africa: are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. Br J Clin Pharmacol. 2021.
31.
go back to reference Ene G, Garcia Raso A, Gonzalez-Dominguez Weber A, Hidalgo-Vega A, Llamas P. Cost of vitamin K antagonist anticoagulant treatment in patients with metallic prosthetic valve in mitral position. SAGE Open Med. 2016;4:2050312116663123.PubMedPubMedCentralCrossRef Ene G, Garcia Raso A, Gonzalez-Dominguez Weber A, Hidalgo-Vega A, Llamas P. Cost of vitamin K antagonist anticoagulant treatment in patients with metallic prosthetic valve in mitral position. SAGE Open Med. 2016;4:2050312116663123.PubMedPubMedCentralCrossRef
32.
go back to reference Guimaraes HP, Lopes RD, de Barros ESPGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383:2117–26. Guimaraes HP, Lopes RD, de Barros ESPGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383:2117–26.
33.
go back to reference Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020;225:69–77.PubMedCrossRef Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020;225:69–77.PubMedCrossRef
34.
go back to reference Okello E, Longenecker CT, Beaton A, Kamya MR, Lwabi P. Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation. BMC Cardiovasc Disord. 2017;17:1–10.CrossRef Okello E, Longenecker CT, Beaton A, Kamya MR, Lwabi P. Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation. BMC Cardiovasc Disord. 2017;17:1–10.CrossRef
35.
go back to reference Yangni-Angate KH, Meneas C, Diby F, Diomande M, Adoubi A, Tanauh Y. Cardiac surgery in Africa: a thirty-five year experience on open heart surgery in Cote d’Ivoire. Cardiovascular Diagnosis and Therapy. 2016;6:S44.PubMedPubMedCentralCrossRef Yangni-Angate KH, Meneas C, Diby F, Diomande M, Adoubi A, Tanauh Y. Cardiac surgery in Africa: a thirty-five year experience on open heart surgery in Cote d’Ivoire. Cardiovascular Diagnosis and Therapy. 2016;6:S44.PubMedPubMedCentralCrossRef
36.
go back to reference Meneguz-Moreno RA, Costa JR Jr, Gomes NL, et al. Very long term follow-up after percutaneous balloon mitral valvuloplasty. JACC Cardiovasc Interv. 2018;11:1945–52.PubMedCrossRef Meneguz-Moreno RA, Costa JR Jr, Gomes NL, et al. Very long term follow-up after percutaneous balloon mitral valvuloplasty. JACC Cardiovasc Interv. 2018;11:1945–52.PubMedCrossRef
37.
go back to reference Nunes MC, Nascimento BR, Lodi-Junqueira L, Tan TC, Athayde GR, Hung J. Update on percutaneous mitral commissurotomy. Heart. 2016;102:500–7.PubMedCrossRef Nunes MC, Nascimento BR, Lodi-Junqueira L, Tan TC, Athayde GR, Hung J. Update on percutaneous mitral commissurotomy. Heart. 2016;102:500–7.PubMedCrossRef
38.
go back to reference Bouleti C, Iung B, Laouenan C, et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation. 2012;125:2119–27.PubMedCrossRef Bouleti C, Iung B, Laouenan C, et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation. 2012;125:2119–27.PubMedCrossRef
39.
go back to reference Nunes MC, Tan TC, Elmariah S, et al. The echo score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation. 2014;129:886–95.PubMedCrossRef Nunes MC, Tan TC, Elmariah S, et al. The echo score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation. 2014;129:886–95.PubMedCrossRef
40.
go back to reference Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communique. Cardiovasc J Afr. 2016;27:184–7.PubMedPubMedCentralCrossRef Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communique. Cardiovasc J Afr. 2016;27:184–7.PubMedPubMedCentralCrossRef
41.
go back to reference Zhang W, Okello E, Nyakoojo W, Lwabi P, Mondo CK. Proportion of patients in the Uganda rheumatic heart disease registry with advanced disease requiring urgent surgical interventions. Afr Health Sci. 2015;15:1182–8.PubMedPubMedCentralCrossRef Zhang W, Okello E, Nyakoojo W, Lwabi P, Mondo CK. Proportion of patients in the Uganda rheumatic heart disease registry with advanced disease requiring urgent surgical interventions. Afr Health Sci. 2015;15:1182–8.PubMedPubMedCentralCrossRef
42.
go back to reference Mirabel M, Grimaldi A, Freers J, Jouven X, Marijon E. Access to cardiac surgery in sub-Saharan Africa. The Lancet. 2015;385:606.CrossRef Mirabel M, Grimaldi A, Freers J, Jouven X, Marijon E. Access to cardiac surgery in sub-Saharan Africa. The Lancet. 2015;385:606.CrossRef
43.
go back to reference Antunes MJ, Finucane K, Kumar AS, Coutinho GF. Surgical management of rheumatic valvular heart disease. In: Carapetis J, Zühlke L, Wilson N, editors. Acute Rheumatic Fever and Rheumatic Heart Disease. Ireland: Elsevier; 2020. p 147–70. Antunes MJ, Finucane K, Kumar AS, Coutinho GF. Surgical management of rheumatic valvular heart disease. In: Carapetis J, Zühlke L, Wilson N, editors. Acute Rheumatic Fever and Rheumatic Heart Disease. Ireland: Elsevier; 2020. p 147–70.
44.
go back to reference Edwin F, Aniteye E, Tettey MM, Tamatey M, Frimpong-Boateng K. Outcome of left heart mechanical valve replacement in West African children-A 15-year retrospective study. J Cardiothorac Surg. 2011;6:1–8.CrossRef Edwin F, Aniteye E, Tettey MM, Tamatey M, Frimpong-Boateng K. Outcome of left heart mechanical valve replacement in West African children-A 15-year retrospective study. J Cardiothorac Surg. 2011;6:1–8.CrossRef
45.
go back to reference Milne O, Barthwal R, Agahari I, Ilton M, Kangaharan N. Management and outcomes of prosthetic valve thrombosis. An Australian case series from the northern territory. Heart Lung Circ. 2020;29:469–74. Milne O, Barthwal R, Agahari I, Ilton M, Kangaharan N. Management and outcomes of prosthetic valve thrombosis. An Australian case series from the northern territory. Heart Lung Circ. 2020;29:469–74.
46.
go back to reference Gündüz S, Kalçık M, Gürsoy MO, Güner A, Özkan M. Diagnosis, treatment & management of prosthetic valve thrombosis: the key considerations. Expert Rev Med Devices. 2020;17:209–21.PubMedCrossRef Gündüz S, Kalçık M, Gürsoy MO, Güner A, Özkan M. Diagnosis, treatment & management of prosthetic valve thrombosis: the key considerations. Expert Rev Med Devices. 2020;17:209–21.PubMedCrossRef
47.
go back to reference Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.PubMedCrossRef Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.PubMedCrossRef
48.
go back to reference Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.PubMedCrossRef Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.PubMedCrossRef
50.
go back to reference Thornburg KL, Jacobson SL, Giraud GD, Morton MJ. Hemodynamic changes in pregnancy. Semin Perinatol. 2000;24:11–4.PubMedCrossRef Thornburg KL, Jacobson SL, Giraud GD, Morton MJ. Hemodynamic changes in pregnancy. Semin Perinatol. 2000;24:11–4.PubMedCrossRef
51.
go back to reference van Hagen IM, Thorne SA, Taha N, et al. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease. Circulation. 2018;137:806–16.PubMedCrossRef van Hagen IM, Thorne SA, Taha N, et al. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the registry of pregnancy and cardiac disease. Circulation. 2018;137:806–16.PubMedCrossRef
52.
go back to reference Beaton A, Okello E, Scheel A, et al. Impact of heart disease on maternal, fetal and neonatal outcomes in a low-resource setting. Heart. 2019;105:755–60.PubMedCrossRef Beaton A, Okello E, Scheel A, et al. Impact of heart disease on maternal, fetal and neonatal outcomes in a low-resource setting. Heart. 2019;105:755–60.PubMedCrossRef
53.
go back to reference Nascimento BR, Sable C, Nunes MCP, et al. Echocardiographic screening of pregnant women by non-physicians with remote interpretation in primary care. Family Practice. 2020. Nascimento BR, Sable C, Nunes MCP, et al. Echocardiographic screening of pregnant women by non-physicians with remote interpretation in primary care. Family Practice. 2020.
54.
go back to reference Arioli F, Ammirati E. Mitral prosthetic valve thrombosis and cardiogenic shock in a limited resource setting in sub-Saharan Africa: a tailored treatment approach. Int J Cardiol. 2015;178:65–6.PubMedCrossRef Arioli F, Ammirati E. Mitral prosthetic valve thrombosis and cardiogenic shock in a limited resource setting in sub-Saharan Africa: a tailored treatment approach. Int J Cardiol. 2015;178:65–6.PubMedCrossRef
55.
go back to reference Basu S, Aggarwal P, Kakani N, Kumar A. Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: in search for a safe anticoagulant regimen during pregnancy. Birth Defects Res A. 2016;106:142–7.CrossRef Basu S, Aggarwal P, Kakani N, Kumar A. Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: in search for a safe anticoagulant regimen during pregnancy. Birth Defects Res A. 2016;106:142–7.CrossRef
56.
go back to reference D’Souza RD, Ostro J, Malinowski A, et al. 662: Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;214:S351.CrossRef D’Souza RD, Ostro J, Malinowski A, et al. 662: Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;214:S351.CrossRef
57.
go back to reference D’Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017;38:1509–16.PubMedPubMedCentralCrossRef D’Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J. 2017;38:1509–16.PubMedPubMedCentralCrossRef
58.
go back to reference Xu Z, Fan J, Luo X, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol. 2016;32:1248. e1–1248. e9. Xu Z, Fan J, Luo X, et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol. 2016;32:1248. e1–1248. e9.
59.
go back to reference French KA, Poppas A. Rheumatic heart disease in pregnancy: global challenges and clear opportunities. Am Heart Assoc. 2018. French KA, Poppas A. Rheumatic heart disease in pregnancy: global challenges and clear opportunities. Am Heart Assoc. 2018.
60.
go back to reference Voleti S, Okello E, Murali M, et al. The personal and clinical impact of screen-detected maternal rheumatic heart disease in Uganda: a prospective follow up study. BMC Pregnancy Childbirth. 2020;20:611.PubMedPubMedCentralCrossRef Voleti S, Okello E, Murali M, et al. The personal and clinical impact of screen-detected maternal rheumatic heart disease in Uganda: a prospective follow up study. BMC Pregnancy Childbirth. 2020;20:611.PubMedPubMedCentralCrossRef
61.
go back to reference Chang AY, Nabbaale J, Nalubwama H, et al. Motivations of women in Uganda living with rheumatic heart disease: a mixed methods study of experiences in stigma, childbearing, anticoagulation, and contraception. PloS One. 2018;13:e0194030. Chang AY, Nabbaale J, Nalubwama H, et al. Motivations of women in Uganda living with rheumatic heart disease: a mixed methods study of experiences in stigma, childbearing, anticoagulation, and contraception. PloS One. 2018;13:e0194030.
62.
go back to reference PREVENTION of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Pediatrics. 1955;15:642–6. PREVENTION of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Pediatrics. 1955;15:642–6.
63.
go back to reference WHO. Rheumatic fever and rheumatic heart disease. In: Organization WH, editor. Geneva, 2001. WHO. Rheumatic fever and rheumatic heart disease. In: Organization WH, editor. Geneva, 2001.
64.
go back to reference WHF. Diagnosis and mangement of acute rheumatic fever and rheumatic heart disease. In: Federation WH, editor. Geneva, Switzerland, 2008. WHF. Diagnosis and mangement of acute rheumatic fever and rheumatic heart disease. In: Federation WH, editor. Geneva, Switzerland, 2008.
65.
go back to reference Australia R. Australian guideline for prevention, diagnosis and mangement of acute rheumatic fever and rheumatic heart disease. In: Zealand NHFoAaCSoAaN, editor. Darwin, Australia, 2020. Australia R. Australian guideline for prevention, diagnosis and mangement of acute rheumatic fever and rheumatic heart disease. In: Zealand NHFoAaCSoAaN, editor. Darwin, Australia, 2020.
66.
go back to reference Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine Penicillin G for the management of RHD: concerns about quality and access, and opportunities for intervention and improvement. Glob Heart. 2013;8:227–34.PubMedCrossRef Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine Penicillin G for the management of RHD: concerns about quality and access, and opportunities for intervention and improvement. Glob Heart. 2013;8:227–34.PubMedCrossRef
67.
go back to reference Taubert K, Marko S. Access to essential medicines: illuminating disparities in the global supply of benzathine penicillin G in the context of rheumatic fever/rheumatic heart disease. J Am Coll Cardiol. 2013;61:e-2004. Taubert K, Marko S. Access to essential medicines: illuminating disparities in the global supply of benzathine penicillin G in the context of rheumatic fever/rheumatic heart disease. J Am Coll Cardiol. 2013;61:e-2004.
68.
go back to reference de Dassel JL, de Klerk N, Carapetis JR, Ralph AP. How many doses make a difference? An Analysis of secondary prevention of rheumatic fever and rheumatic heart disease. J Am Heart Assoc. 2018;7:e010223. de Dassel JL, de Klerk N, Carapetis JR, Ralph AP. How many doses make a difference? An Analysis of secondary prevention of rheumatic fever and rheumatic heart disease. J Am Heart Assoc. 2018;7:e010223.
69.
go back to reference Kevat PM, Reeves BM, Ruben AR, Gunnarsson R. Adherence to secondary prophylaxis for acute rheumatic fever and rheumatic heart disease: a systematic review. Curr Cardiol Rev. 2017;13:155–66.PubMedPubMedCentralCrossRef Kevat PM, Reeves BM, Ruben AR, Gunnarsson R. Adherence to secondary prophylaxis for acute rheumatic fever and rheumatic heart disease: a systematic review. Curr Cardiol Rev. 2017;13:155–66.PubMedPubMedCentralCrossRef
70.
go back to reference Read C, Mitchell AG, de Dassel JL, et al. Qualitative evaluation of a complex intervention to improve rheumatic heart disease secondary prophylaxis. J Am Heart Assoc. 2018;7. Read C, Mitchell AG, de Dassel JL, et al. Qualitative evaluation of a complex intervention to improve rheumatic heart disease secondary prophylaxis. J Am Heart Assoc. 2018;7.
71.
go back to reference Ralph AP, de Dassel JL, Kirby A, et al. Improving delivery of secondary prophylaxis for rheumatic heart disease in a high-burden setting: outcome of a stepped-wedge, community, randomized trial. J Am Heart Assoc. 2018;7. Ralph AP, de Dassel JL, Kirby A, et al. Improving delivery of secondary prophylaxis for rheumatic heart disease in a high-burden setting: outcome of a stepped-wedge, community, randomized trial. J Am Heart Assoc. 2018;7.
72.
go back to reference Balbaa A, ElGuindy A, Pericak D, Yacoub MH, Schwalm JD. An evaluation of secondary prophylaxis for rheumatic heart disease in rural Egypt. Glob Cardiol Sci Pract. 2015;2015:40.PubMedPubMedCentralCrossRef Balbaa A, ElGuindy A, Pericak D, Yacoub MH, Schwalm JD. An evaluation of secondary prophylaxis for rheumatic heart disease in rural Egypt. Glob Cardiol Sci Pract. 2015;2015:40.PubMedPubMedCentralCrossRef
73.
go back to reference Thompson SB, Brown CH, Edwards AM, Lindo JL. Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever. Jamaica Pathog Glob Health. 2014;108:229–34.PubMedCrossRef Thompson SB, Brown CH, Edwards AM, Lindo JL. Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever. Jamaica Pathog Glob Health. 2014;108:229–34.PubMedCrossRef
74.
go back to reference Engelman D, Ah Kee M, Mataika RL, et al. Secondary prevention for screening detected rheumatic heart disease: opportunities to improve adherence. Trans R Soc Trop Med Hyg. 2017;111:154–62.PubMedCrossRef Engelman D, Ah Kee M, Mataika RL, et al. Secondary prevention for screening detected rheumatic heart disease: opportunities to improve adherence. Trans R Soc Trop Med Hyg. 2017;111:154–62.PubMedCrossRef
75.
go back to reference Mincham CM, Toussaint S, Mak DB, Plant AJ. Patient views on the management of rheumatic fever and rheumatic heart disease in the Kimberley: a qualitative study. Aust J Rural Health. 2003;11:260–5.PubMedCrossRef Mincham CM, Toussaint S, Mak DB, Plant AJ. Patient views on the management of rheumatic fever and rheumatic heart disease in the Kimberley: a qualitative study. Aust J Rural Health. 2003;11:260–5.PubMedCrossRef
76.
go back to reference Huck DM, Nalubwama H, Longenecker CT, Frank SH, Okello E, Webel AR. A qualitative examination of secondary prophylaxis in rheumatic heart disease: factors influencing adherence to secondary prophylaxis in Uganda. Glob Heart. 2015;10:63–69 e1. Huck DM, Nalubwama H, Longenecker CT, Frank SH, Okello E, Webel AR. A qualitative examination of secondary prophylaxis in rheumatic heart disease: factors influencing adherence to secondary prophylaxis in Uganda. Glob Heart. 2015;10:63–69 e1.
77.
go back to reference Barker H, Oetzel JG, Scott N, Morley M, Carr PEA, Oetzel KB. Enablers and barriers to secondary prophylaxis for rheumatic fever among Maori aged 14–21 in New Zealand: a framework method study. Int J Equity Health. 2017;16:201.PubMedPubMedCentralCrossRef Barker H, Oetzel JG, Scott N, Morley M, Carr PEA, Oetzel KB. Enablers and barriers to secondary prophylaxis for rheumatic fever among Maori aged 14–21 in New Zealand: a framework method study. Int J Equity Health. 2017;16:201.PubMedPubMedCentralCrossRef
78.
go back to reference Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience. Indian Heart J. 2002;54:54–8.PubMed Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience. Indian Heart J. 2002;54:54–8.PubMed
79.
go back to reference Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust. 2006;184:514–7.PubMedCrossRef Harrington Z, Thomas DP, Currie BJ, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. Med J Aust. 2006;184:514–7.PubMedCrossRef
80.
go back to reference World Health Organization. Report of the Commission on Macroeconomics and health. 2002. World Health Organization. Report of the Commission on Macroeconomics and health. 2002.
81.
go back to reference Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué: cardiovascular topics. Cardiovasc J Afr. 2016;27:184–7.PubMedPubMedCentralCrossRef Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué: cardiovascular topics. Cardiovasc J Afr. 2016;27:184–7.PubMedPubMedCentralCrossRef
82.
go back to reference Oyebamiji O. The household economic impact of rheumatic heart disease (RHD) in South Africa. University of Cape Town, 2018. Oyebamiji O. The household economic impact of rheumatic heart disease (RHD) in South Africa. University of Cape Town, 2018.
83.
go back to reference Hellebo AG, Zuhlke LJ, Watkins DA, Alaba O. Health system costs of rheumatic heart disease care in South Africa. BMC Public Health. 2021;21:1–11.CrossRef Hellebo AG, Zuhlke LJ, Watkins DA, Alaba O. Health system costs of rheumatic heart disease care in South Africa. BMC Public Health. 2021;21:1–11.CrossRef
84.
85.
go back to reference Arvind B, Saxena A, Kazi DS, Bolger AF. Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: a registry-based data from a tertiary care center in Northern India. Indian Heart J. 2021;73:169–73.PubMedCrossRef Arvind B, Saxena A, Kazi DS, Bolger AF. Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: a registry-based data from a tertiary care center in Northern India. Indian Heart J. 2021;73:169–73.PubMedCrossRef
86.
go back to reference Haynes E, Mitchell A, Enkel S, Wyber R, Bessarab D. Voices behind the statistics: a systematic literature review of the lived experience of rheumatic heart disease. Int J Environ Res Public Health. 2020;17:1347.PubMedCentralCrossRef Haynes E, Mitchell A, Enkel S, Wyber R, Bessarab D. Voices behind the statistics: a systematic literature review of the lived experience of rheumatic heart disease. Int J Environ Res Public Health. 2020;17:1347.PubMedCentralCrossRef
87.
go back to reference Monib D, Wahdan I, Hasab A, Zaher S. Health related quality of life of rheumatic heart disease patients in Alexandria: an intervention approach. Journal of High Institute of Public Health. 2013;43:112–20.CrossRef Monib D, Wahdan I, Hasab A, Zaher S. Health related quality of life of rheumatic heart disease patients in Alexandria: an intervention approach. Journal of High Institute of Public Health. 2013;43:112–20.CrossRef
88.
go back to reference Riaz A, Hanif MI, Khan IH, Hanif A, Mughal S, Anwer A. Quality of life in patients with rheumatic heart disease. J Pakistan Med Assoc. 2018;68:370–5. Riaz A, Hanif MI, Khan IH, Hanif A, Mughal S, Anwer A. Quality of life in patients with rheumatic heart disease. J Pakistan Med Assoc. 2018;68:370–5.
89.
go back to reference Bradley-Hewitt T, Dantin A, Ploutz M, et al. The impact of echocardiographic screening for rheumatic heart disease on patient quality of life. J Pediatr. 2016;175:123–9.PubMedCrossRef Bradley-Hewitt T, Dantin A, Ploutz M, et al. The impact of echocardiographic screening for rheumatic heart disease on patient quality of life. J Pediatr. 2016;175:123–9.PubMedCrossRef
90.
go back to reference Zühlke L, Perkins S, Cembi S. Rheumatic heart disease patient event: Cape Town hosts 4th annual listen to my heart rheumatic heart disease for patients at the South African heart association meeting in 2017. Oxford University Press, 2018. Zühlke L, Perkins S, Cembi S. Rheumatic heart disease patient event: Cape Town hosts 4th annual listen to my heart rheumatic heart disease for patients at the South African heart association meeting in 2017. Oxford University Press, 2018.
91.
go back to reference Macleod CK, Bright P, Steer AC, Kim J, Mabey D, Parks T. Neglecting the neglected: the objective evidence of underfunding in rheumatic heart disease. Trans R Soc Trop Med Hyg. 2019;113:287–90.PubMedPubMedCentralCrossRef Macleod CK, Bright P, Steer AC, Kim J, Mabey D, Parks T. Neglecting the neglected: the objective evidence of underfunding in rheumatic heart disease. Trans R Soc Trop Med Hyg. 2019;113:287–90.PubMedPubMedCentralCrossRef
94.
go back to reference Beaton A, Kamalembo FB, Dale J, et al. The American Heart Association’s call to action for reducing the global burden of rheumatic heart disease: a policy statement from the American Heart Association. Circulation. 2020;142:e358–68.PubMedCrossRef Beaton A, Kamalembo FB, Dale J, et al. The American Heart Association’s call to action for reducing the global burden of rheumatic heart disease: a policy statement from the American Heart Association. Circulation. 2020;142:e358–68.PubMedCrossRef
95.
go back to reference Mayosi BM, Gamra H, Dangou JM, Kasonde J. 2nd All-Africa Workshop on Rheumatic Fever and Rheumatic Heart Disease participants. Rheumatic heart disease in Africa: the Mosi-o-Tunya call to action. Lancet Glob Health. 2014;2:e438–9. Mayosi BM, Gamra H, Dangou JM, Kasonde J. 2nd All-Africa Workshop on Rheumatic Fever and Rheumatic Heart Disease participants. Rheumatic heart disease in Africa: the Mosi-o-Tunya call to action. Lancet Glob Health. 2014;2:e438–9.
96.
go back to reference Dale JB, Walker MJ. Update on group A streptococcal vaccine development. Curr Opin Infect Dis. 2020;33:244–250. Dale JB, Walker MJ. Update on group A streptococcal vaccine development. Curr Opin Infect Dis. 2020;33:244–250.
Metadata
Title
The Global Impact of Rheumatic Heart Disease
Authors
Joselyn Rwebembera
Andrea Z. Beaton
Sarah R. de Loizaga
Rodrigo T. L. Rocha
Nakagaayi Doreen
Isaac Ssinabulya
Emmy Okello
Clara L. Fraga
Bruno F. Galdino
Maria Carmo P. Nunes
Bruno R. Nascimento
Publication date
01-11-2021
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 11/2021
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-021-01592-2

Other articles of this Issue 11/2021

Current Cardiology Reports 11/2021 Go to the issue

Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Physical Activity and Cardiorespiratory Fitness: Vital Signs for Cardiovascular Risk Assessment

Cardiovascular Genomics (P Natarajan, Section Editor)

Atrial Fibrillation Genomics: Discovery and Translation

New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

Left Bundle Branch Area Pacing: Implant Technique, Definitions, Outcomes, and Complications

New Therapies for Cardiovascular Disease (AA Bavry and MR Massoomi, Section Editors)

Is Coronary Brachytherapy Staging a Comeback for the Treatment of In-Stent Restenosis?

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?